Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity

Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
  • Regeneron Pharmaceuticals Inc REGN earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. 
  • Sales decreased 44% to $2.85 billion, surpassing the analysts' consensus of $2.79 billion.
  • Total revenues excluding REGEN-COV and Ronapreve revenues increased by 20%. No REGEN-COV sales were recorded as the company had completed its final deliveries under its agreements with the U.S. government.
  • Q2 U.S. Eylea sales increased 14% Y/Y to $1.62 billion. 
  • The company obtained the exclusive right to Libtayo from Sanofi SA SNY for a $900 million up-front payment. Sanofi is eligible to receive a $100 million regulatory milestone and $100 million in sales-based milestones.
  • Concurrently, Regeneron announced initial data from an ongoing Phase 1/2 trial of REGN5678 in combination with Libtayo (cemiplimab) in advanced metastatic castration-resistant prostate cancer. 
  • Preliminary data showed dose-dependent anti-tumor activity. 
  • At the lowest dose levels (cohorts 1-5), there was almost no evidence of anti-tumor activity, with only 1 of 17 patients showing a decrease (22%) in prostate-specific antigen.
  • At the higher dose levels (cohorts 6-8), evidence of dose-dependent anti-tumor activity was generally seen within six weeks of starting combination treatment.
  • Price Action: REGN shares are up 8.16% at $621.88 during the market session on the last check Wednesday

Posted In: Briefswhy it's movingBiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneral